EVG.L Share News (EVG)

EVG.L Information

There is currently no data for EVG

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Wed, 07th Apr 2021 16:22

Evgen Pharma PLC - clinical stage drug development company - Notes that sulforaphane, the active ingredient in SFX-01, prevents virus-induced cell death in vitro induced by some variants of coronavirus. Evgen's SFX-01 is a druggable, clinical grade medicine currently at the clinical trial stage containing synthetic sulforaphane in a stable complex.

"We anticipate receiving the outcome of the interim analysis of the first 100 patients completing the study during this second quarter of 2021," says Chief Executive Huw Jones.

Current stock price: 8.28 pence, up 1.0% on Wednesday

Year-to-date change: down 19%

By Evelina Grecenko; evelinagrecenko@alliancenews.com

More News

22 Mar 2021 14:32

IN BRIEF: Evgen Pharma names Helen Kuhlman as chief business officer

22 Mar 2021 09:08

Evgen appoints Helen Kuhlman as chief business officer

(Sharecast News) - Clinical-stage drug development company Evgen announced on Monday that Helen Kuhlman had been appointed to the post of chief business officer, taking up the role from 1 April.

11 Mar 2021 20:08

IN BRIEF: Evgen says no patient safety concerns in STAR Covid-19 trial

11 Mar 2021 15:12

Evgen Covid-19 trial given all-clear on safety and data

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Thursday that after a review of the first 60 patients enrolled, the data safety monitoring committee for the 'STAR' Covid-19 trial had concluded that there were no concerns over patient safety or data quality that would prevent its continuation.

3 Mar 2021 20:16

TRADING UPDATES: Cambria drives on amid virus; Argo crypto mining up

24 Feb 2021 16:09

UK Shareholder Meetings Calendar - Next 7 Days

17 Feb 2021 15:10

Evgen makes progress with recruitment in 'STAR' trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma said on Wednesday that a total of 102 patients had been recruited and randomised to the 'STAR', or 'SFX-01 Treatment for Acute Respiratory infections', trial.

17 Feb 2021 11:15

IN BRIEF: Evgen Pharma Recruits Over 100 For Respiratory Drug Trial

3 Feb 2021 11:49

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

2 Feb 2021 17:45

IN BRIEF: Evgen Pharma's GBP11 Fundraise To Support Lead Candidate

22 Jan 2021 08:53

Evgen Shares Rise On Further Positive Test Results For SFX-01

21 Jan 2021 13:20

IN BRIEF: Evgen Pharma Notes Positive Preclinical Data For SFX-01

19 Jan 2021 17:34

IN BRIEF: Evgen Pharma Recruits Patients For STAR-Covid-19 Trial

10 Dec 2020 17:07

UK EARNINGS SUMMARY: Character Group Lowers Dividend As Profit Drops

10 Dec 2020 15:45

Evgen Pharma performs in line with forecasts in first half

(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported financial performance in line with its expectations in its first half on Thursday, with revenue coming in at £0.19m, compared to nil a year earlier.

Latest Share Chat

EVG.L Share News (EVG)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Login to your account

Quickpicks are a member only feature

Login to your account